查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1694060

PDE9A抑制劑:策略性市場洞察和開發平台(管線)的展望-2025年

PDE9A Inhibitors: Strategic Market Insights & Pipeline Outlook - 2025
出版日期: | 出版商: Mellalta Meets LLP | 英文 100 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

PDE9A 抑制劑領域正處於轉折點，市場不斷增長，未滿足的需求巨大，臨床證據有力。擁有一流選擇性、臨床差異化和策略合作夥伴關係的公司預計將在心血管和認知治療領域抓住數十億美元的機會。

磷酸二酯酶 9A (PDE9A) 已成為藥物開發的寶貴靶點，特別是由於其在心血管和神經退化性疾病中的作用。透過調節環核苷酸水平，PDE9A 抑制劑提供了一種新的作用機制，可能為心臟衰竭（HFpEF、HFrEF）、阿茲海默症和精神分裂症帶來突破性的治療。然而，儘管PDE9A抑制劑前景光明，但它尚未獲得臨床批准，這給藥物開發商和投資者帶來了高風險、高回報的機會。

PDE9A 在細胞內訊號傳導中起著關鍵作用，調節 cGMP 和 cAMP 的水平。透過阻斷 PDE9A 的活性，抑制劑可以阻止這些重要訊號分子的降解，從而增強血管舒張、神經保護和代謝調節。透過這些機制，PDE9A 抑制劑可能代表心血管和神經系統治療範式中的突破性療法，特別是在涉及 cGMP 失調的病理學中。

PDE9A 抑制劑市場非常活躍，各大公司正在開發許多活性候選藥物，其中包括：Cardurion Pharmaceuticals 憑藉兩項正在開發的資產引領市場。 Ignota Labs 已籌集 690 萬美元的種子資金，專注於人工智慧驅動的藥物研發。衛材和勃林格殷格翰正在開發用於治療心臟衰竭和神經系統疾病的 PDE9A 抑制劑。

儘管有這樣的勢頭，但選擇性的課題依然存在。具體來說，它將 PDE9A 與 PDE1 等其他磷酸二酯酶區分開來，後者在受到抑制時可能會引起與中樞神經系統相關的副作用。

廣譜 PDE 抑制劑市場規模預計將從 2024 年的 40.6 億美元成長到 2032 年的 69.2 億美元，複合年增長率為 6.88%。

由於 PDE9A 抑制劑尚未獲得批准，早期投資可能提供先發優勢，特別是在合作、收購和授權交易方面。

本報告提供全球PDE9A抑制劑市場相關調查，提供市場現狀，以及收購，授權及聯盟契約，競爭情形，市場機會等資訊。

目錄

第1章 報告書概要

第2章 概要

  • PDE9A抑制劑的介紹與作用
  • PDE9A 抑制劑的潛在問題
  • PDE9A 抑制劑：心血管領域極具前景的標靶
  • PDE9A抑制劑的臨床應用

第3章 PDE9A抑制劑開發平台分析

  • 概要
  • 指示/階段資產
  • 依開發階段劃分的在研產品
  • PDE9A 抑制劑的競爭格局
  • 公司和階段劃分的管道產品
  • PDE9A 抑制劑的臨床和監管時間表

第4章 PDE9A抑制劑的收購，授權及聯盟契約

  • PDE9A 抑制劑收購、授權和交易價值
  • PDE9A 抑制劑收購與授權（按交易類型和階段劃分的總價值）
  • 正在開發中有前景的技術

第5章 PDE9A抑制劑開發平台(管線)的形勢

  • 簡介概要
  • 後期階段的資產比較概要
  • PDE9A抑制劑開發平台(管線)的藥物簡介
    • CRD-740(Cardurion Pharmaceuticals)
    • tobinontorin(Cardurion Pharmaceuticals)
    • irusenotorin(Eisai)
    • osoresunontorin(Boehringer Ingelheim)
    • PDE9A抑制劑(Ignota Labs)
    • 其他

第6章 PDE9A抑制劑的未來展望

第7章 SWOT分析

第8章 附錄

簡介目錄

The PDE9A inhibitor space is at an inflection point-backed by a growing market, significant unmet needs, and strong clinical rationale. Companies positioned with best-in-class selectivity, clinical differentiation, and strategic partnerships stand to capture a multi-billion-dollar opportunity in cardiovascular and cognitive therapeutics.

Phosphodiesterase 9A (PDE9A) has emerged as a high-value target in drug development, particularly for its role in cardiovascular and neurodegenerative diseases. By modulating cyclic nucleotide levels, PDE9A inhibitors offer a novel mechanism of action that could translate into groundbreaking therapies for heart failure (HFpEF, HFrEF), Alzheimer's disease, and schizophrenia. However, despite their promise, no PDE9A inhibitor has been approved for clinical use yet-leaving a high-risk, high-reward opportunity for drug developers and investors.

Mechanism of Action: A New Class of cGMP Modulators

PDE9A plays a pivotal role in intracellular signal transduction, regulating cGMP and cAMP levels. By blocking PDE9A activity, inhibitors prevent the degradation of these key signaling molecules, leading to enhanced vasodilation, neuroprotection, and metabolic regulation. This mechanism positions PDE9A inhibitors as a potential breakthrough in cardiovascular and neurological treatment paradigms, particularly for conditions where cGMP dysregulation is implicated.

Market Overview: Competitive and Expanding Landscape

The PDE9A inhibitors market is highly dynamic, with many active drug candidates in development by key players, including:

  • Cardurion Pharmaceuticals - Leading the pipeline with two assets under development.
  • Ignota Labs - Backed by $6.9M in seed funding, focusing on AI-driven drug discovery.
  • Eisai & Boehringer Ingelheim - Exploring PDE9A inhibitors across heart failure and neurological indications.

Clinical progress is accelerating, with:

  • 60% of PDE9A inhibitors in Phase II trials
  • 20% in Phase I trials
  • 20% in preclinical development

Despite this momentum, selectivity challenges remain-particularly in distinguishing PDE9A from other phosphodiesterases like PDE1, which, if inhibited, could lead to CNS-related side effects.

Commercial Opportunity: Market Growth & Investment Potential

The broader PDE inhibitors market is projected to grow from $4.06 billion in 2024 to $6.92 billion by 2032 at a CAGR of 6.88%. This surge is fueled by:

  • The rising prevalence of heart failure (expected to cost the U.S. $70 billion annually by 2030).
  • The Alzheimer's market reaching $1 trillion in costs by 2050, highlighting the urgent need for disease-modifying treatments.
  • Increased biopharma investment in neurotherapeutics and cardiovascular innovations.

With no approved PDE9A inhibitors yet, early-stage investments could lead to first-mover advantages, especially in partnerships, acquisitions, and licensing deals.

Strategic Insights from Mellalta Meets' 2025 Report

The PDE9A Inhibitor - Pipeline Analytics 2025 Report by Mellalta Meets provides in-depth market intelligence, covering:

  • Pipeline Breakdown - Companies, Products in various development phases.
  • Clinical Trial Analysis - Key regions, interventions, and trial outcomes.
  • Competitive Intelligence - Acquisition targets, licensing deals, and funding trends.
  • Indication Prioritization - Identifying high-value opportunities in PDE9A drug development.

Table of Content

1. REPORT OVERVIEW

2. OVERVIEW

  • 2.1. Introduction and Role of PDE9A inhibitors
  • 2.2. Potential Concern with PDE9A Inhibitors
  • 2.3. PDE9A Inhibitors: A Highly-Potential Target in Cardiovascular Space
  • 2.4. Clinical Applications of PDE9A Inhibitors

3. PDE9A INHIBITOR PIPELINE ANALYSIS

  • 3.1. Overview
  • 3.2. Assets by Indication/Phase
  • 3.3. Pipeline Products by Stage of Development
  • 3.4. PDE9A Inhibitor Competitive Landscape
  • 3.5. Pipeline Products by Company and Phases
  • 3.6. PDE9A Inhibitor Clinical & Regulatory Timelines

4. PDE9A INHIBITOR ACQUISITIONS, LICENSING AND COLLABORATION DEALS

  • 4.1. PDE9A Inhibitor Acquisitions, Licensing and Deal values
  • 4.2. PDE9A Inhibitor Acquisitions, Licensing by Transaction type and total amount size by Phases
  • 4.3. Promising Technologies Under development

5. PDE9A Inhibitor PIPELINE LANDSCAPE

  • 5.1. Profile at Glance
  • 5.2. Late-Stage Assets Comparisons At-a-glance
  • 5.3. PDE9A Inhibitor Pipeline Drug Profiles
    • 5.3.1. CRD-740 (Cardurion Pharmaceuticals)
      • 5.3.1.1. Product Profile & Description
      • 5.3.1.2. Collaborations
      • 5.3.1.3. Other Developments
      • 5.3.1.4. Clinical Trials
    • 5.3.2. Tovinontrine (Cardurion Pharmaceuticals)
      • 5.3.2.1. Product Profile & Description
      • 5.3.2.2. Collaborations
      • 5.3.2.3. Other Developments
      • 5.3.2.4. Clinical Trials
    • 5.3.3. Irsenontrine (Eisai)
      • 5.3.3.1. Product Profile & Description
      • 5.3.3.2. Collaborations
      • 5.3.3.3. Other Developments
      • 5.3.3.4. Clinical Trials
    • 5.3.4. Osoresnontrine (Boehringer Ingelheim)
      • 5.3.4.1. Product Profile & Description
      • 5.3.4.2. Collaborations
      • 5.3.4.3. Other Developments
      • 5.3.4.4. Clinical Trials
    • 5.3.5. PDE9A inhibitor (Ignota Labs)
      • 5.3.5.1. Product Profile & Description
      • 5.3.5.2. Collaborations
      • 5.3.5.3. Other Developments
    • 5.3.6. Others...

6. PDE9A INHIBITOR FUTURE PROSPECTS

7. SWOT ANALYSIS

8. APPENDIX